MOVENTIG

How to Prescribe MOVENTIG¹

When symptoms of constipation persist after 4 days of laxative therapy, consider MOVENTIG.

MOVENTIG 25mg is a convenient once-daily tablet to be taken:

• In the morning
• On an empty stomach at least 30 minutes prior to the first meal of the day or two hours after the first meal of the day
• When initiating MOVENTIG therapy, it is recommended that all currently used maintenance laxative therapy is halted until the clinical effect of MOVENTIG is determined
• For patients who are unable to swallow the tablet whole, the tablet can be crushed to a powder and mixed in half a glass of water (120 ml) and drunk immediately. The glass should be rinsed with a further half glass of water (120 ml) and the contents drunk
• Refer to section 6.6 of the SmPC for further information on administration through a nasogastric tube

MOVENTIG is contraindicated in patients with: 

• Known or suspected GI obstruction or in patients at increased risk of recurrent obstruction, due to potential for GI perforation
• Concomitant use of strong CYP3A4 inhibitors or inducers
• Patients with underlying cancer who are at heightened risk of GI perforation, such as those with:
  • Underlying malignancies of GI tract of peritoneum
  • Recurrent or advanced ovarian cancer
  • Vascular endothelial growth factor (VEGF) inhibitor treatment

For full information of contraindications, warning and precautions, please refer to the Summary of Product Characteristics.

* Definition of laxative inadequate responder (LIR): In the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.¹